Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CCR1 | P32246 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | CCR8 | P51685 | 2/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12686649 | 1.00 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8PDGFRB | |
| SCHEMBL12686653 | 0.84 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8PDGFRB | |
| SCHEMBL16155307 | 0.84 | ALDH1A1 (0.50) | CYP1A2CCR1CCR5CCR8BACE1 | |
| SCHEMBL4572536 | 0.83 | CYP1A2 (0.65) | CYP1A2CCR1CCR5CCR8BACE1 | |
| SCHEMBL3868339 | 0.83 | BACE1 (0.47) | CYP1A2PDGFRBPDGFRABACE1PIK3CA | |
| SCHEMBL12909530 | 0.77 | EGFR (0.50) | PDGFRBPDGFRABACE1KDM4EPDE3B | |
| SCHEMBL25112013 | 0.77 | CYP1A2 (0.45) | CYP1A2CCR1CCR5CCR8PDGFRB | |
| SCHEMBL21988901 | 0.76 | MAP4K4 (0.54) | PDGFRBPDGFRABACE1TSHRKDM4E | |
| SCHEMBL16289408 | 0.76 | BACE1 (0.41) | CYP1A2PDGFRBPDGFRABACE1TSHR | |
| SCHEMBL21632275 | 0.76 | CYP1A2 (0.57) | CYP1A2CCR1CCR5CCR8PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | CYP1A2 1890/4885CCR1 696/4885CCR5 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.